image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 12.52
-4.06 %
$ 3.23 B
Market Cap
3.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OGN stock under the worst case scenario is HIDDEN Compared to the current market price of 12.5 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OGN stock under the base case scenario is HIDDEN Compared to the current market price of 12.5 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OGN stock under the best case scenario is HIDDEN Compared to the current market price of 12.5 USD, Organon & Co. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OGN

image
$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
6.4 B REVENUE
2.24%
1.49 B OPERATING INCOME
11.98%
864 M NET INCOME
-15.54%
939 M OPERATING CASH FLOW
17.52%
-513 M INVESTING CASH FLOW
-97.31%
-368 M FINANCING CASH FLOW
35.33%
1.59 B REVENUE
0.63%
0 OPERATING INCOME
0.00%
109 M NET INCOME
-69.64%
390 M OPERATING CASH FLOW
176.60%
-296 M INVESTING CASH FLOW
-208.77%
-82 M FINANCING CASH FLOW
-5.13%
Balance Sheet Organon & Co.
image
Current Assets 4.35 B
Cash & Short-Term Investments 675 M
Receivables 1.36 B
Other Current Assets 2.32 B
Non-Current Assets 8.75 B
Long-Term Investments 0
PP&E 1.17 B
Other Non-Current Assets 7.58 B
5.15 %10.37 %17.67 %8.92 %57.90 %Total Assets$13.1b
Current Liabilities 2.72 B
Accounts Payable 1.15 B
Short-Term Debt 20 M
Other Current Liabilities 1.54 B
Non-Current Liabilities 9.91 B
Long-Term Debt 8.86 B
Other Non-Current Liabilities 1.05 B
9.13 %12.23 %70.16 %8.32 %Total Liabilities$12.6b
EFFICIENCY
Earnings Waterfall Organon & Co.
image
Revenue 6.4 B
Cost Of Revenue 2.69 B
Gross Profit 3.72 B
Operating Expenses 2.23 B
Operating Income 1.49 B
Other Expenses 622 M
Net Income 864 M
7b7b6b6b5b5b4b4b3b3b2b2b1b1b006b(3b)4b(2b)1b(622m)864mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
58.02% GROSS MARGIN
58.02%
23.21% OPERATING MARGIN
23.21%
13.49% NET MARGIN
13.49%
183.05% ROE
183.05%
6.59% ROA
6.59%
15.29% ROIC
15.29%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organon & Co.
image
4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m002018201820192019202020202021202120222022202320232024202420252025
Net Income 864 M
Depreciation & Amortization 132 M
Capital Expenditures -175 M
Stock-Based Compensation 105 M
Change in Working Capital 0
Others -2 M
Free Cash Flow 764 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organon & Co.
image
Wall Street analysts predict an average 1-year price target for OGN of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OGN Lowest Price Target Wall Street Target
24 USD 91.69%
OGN Average Price Target Wall Street Target
24 USD 91.69%
OGN Highest Price Target Wall Street Target
24 USD 91.69%
Price
Max Price Target
Min Price Target
Average Price Target
2424222220201818161614141212May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
1.92% DIVIDEND YIELD
0.28 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.201.201.001.000.800.800.600.600.400.400.200.200.000.000.280.280.280.280.280.280.280.280.280.280.280.281.120.281.120.281.120.280.840.002021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Organon & Co.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. zacks.com - 1 week ago
Why Organon (OGN) Could Beat Earnings Estimates Again Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 1 week ago
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 1 week ago
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. businesswire.com - 1 week ago
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11. businesswire.com - 1 week ago
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session. zacks.com - 1 week ago
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors In the closing of the recent trading day, Organon (OGN) stood at $15.39, denoting a -1.35% change from the preceding trading day. zacks.com - 2 weeks ago
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com - 3 weeks ago
Organon (OGN) Advances While Market Declines: Some Information for Investors Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close. zacks.com - 3 weeks ago
Why Organon Is A Top Pick For Income Investors In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector. seekingalpha.com - 3 weeks ago
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently. businesswire.com - 1 month ago
High-Yield Healthcare: 3 Stocks With Strong Dividends When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income. marketbeat.com - 1 month ago
8. Profile Summary

Organon & Co. OGN

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 3.23 B
Dividend Yield 1.92%
Description Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Contact 30 Hudson Street, Jersey City, NJ, 07302 https://www.organon.com
IPO Date May 14, 2021
Employees 10000
Officers Mr. Daniel Karp Head of Corporate Development Mr. Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary Ms. Rebecca Lowell Edwards Chief Communications Officer Mr. Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply Mr. Aaron Falcione Executive Vice President & Chief Human Resources Officer Ms. Susan O'Neal Chief Ethics & Compliance Officer Mr. Matthew M. Walsh C.F.A. Executive Vice President & Chief Financial Officer Ms. Jennifer Halchak Head of Investor Relations Mr. Kevin Ali Chief Executive Officer & Director Mr. Vittorio Nisita Executive Vice President & Head of Global Business Services